tag:www.gov.uk,2005:/drug-safety-updateDrug Safety Update about Haematology and oncology2025-01-28T14:00:09+00:00HM 바카라 사이트tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-december-20242025-01-28T14:00:09+00:00Letters and medicine recalls sent to healthcare professionals in December 2024A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.바카라 사이트¯ tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-september-20242024-10-24T11:00:11+01:00Letters and medicine recalls sent to healthcare professionals in September 2024 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.tag:www.gov.uk,2005:/drug-safety-update/yellow-card-biobank-call-to-contribute-to-study-of-genetic-links-to-side-effects2024-08-21T11:00:45+01:00Yellow Card Biobank: call to contribute to study of genetic links to side effectsSupport this initiative to explore whether there is a genetic basis of side effects associated with direct-acting oral anticoagulants (DOACs) and allopurinol. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-july-20242024-08-21T11:00:39+01:00Letters and medicine recalls sent to healthcare professionals in July 2024 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-june-20242024-07-23T14:01:07+01:00Letters and medicine recalls sent to healthcare professionals in June 2024 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. tag:www.gov.uk,2005:/drug-safety-update/warfarin-be-alert-to-the-risk-of-drug-interactions-with-tramadol2024-06-20T11:11:09+01:00Warfarin: be alert to the risk of drug interactions with tramadolTaking warfarin and tramadol together can cause harmful drug interactions, which can raise the International Normalised Ratio (INR), and result in severe bruising and bleeding, which in some patients could be fatal.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-april-20242024-05-29T14:32:40+01:00Letters and medicine recalls sent to healthcare professionals in April 2024 A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices, and information about the publication of two recent Device Safety Information pages. The article also includ바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-february-20242024-03-27T11:53:02+00:00Letters and medicine recalls sent to healthcare professionals in February 2024A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.tag:www.gov.uk,2005:/drug-safety-update/pseudoephedrine-very-rare-risk-of-posterior-reversible-encephalopathy-syndrome-pres-and-reversible-cerebral-vasoconstriction-syndrome-rcvs2024-02-20T11:01:34+00:00Pseudoephedrine: very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)There have been very rare reports of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with pseudoephedrine. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-january-20242024-02-20T11:01:30+00:00Letters and medicine recalls sent to healthcare professionals in January 2024A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-august-20232023-09-26T14:30:07+01:00Letters and medicine recalls sent to healthcare professionals in August 2023A summary of recent letters and notifications sent to healthcare professionals about medicines, and a recent National Patient Safety Alert highlighting the risk of deaths and serious injuries from entrapment or falls relatin바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-july-20232023-08-30T10:31:08+01:00Letters and medicine recalls sent to healthcare professionals in July 2023A summary of recent letters and notifications sent to healthcare professionals about medicines.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-may-20232023-06-27T13:34:54+01:00Letters and medicine recalls sent to healthcare professionals in May 2023A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices and details of two recent MHRA National Patient Safety Alerts to remove from service Philips Health Systems V바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-march-20232023-04-26T11:39:21+01:00Letters and medicine recalls sent to healthcare professionals in March 2023 A summary of recent letters and notifications sent to healthcare professionals about medicines. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-december-20222023-01-25T13:24:51+00:00Letters and medicine recalls sent to healthcare professionals in December 2022A summary of recent letters and notifications sent to healthcare professionals about medicines.
tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-september-20222022-10-25T14:43:16+01:00Letters and medicine recalls sent to healthcare professionals in September 2022A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-june-20222022-07-21T11:03:37+01:00Letters and medicine recalls sent to healthcare professionals in June 2022A summary of recent letters and notifications sent to healthcare professionals about medicines.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-april-20222022-05-17T13:11:33+01:00Letters and medicine recalls sent to healthcare professionals in April 2022A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. Includes a recent recall of Accupro (quinapril hydrochloride) and advice on Xagrid (anagrelide hydrochloride바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-december-20212022-01-18T13:18:06+00:00Letters and medicine recalls sent to healthcare professionals in December 2021A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/venetoclax-venclyxtov-updated-recommendations-on-tumour-lysis-syndrome-tls2021-12-10T11:01:39+00:00Venetoclax (Venclyxtoâ–¼): updated recommendations on tumour lysis syndrome (TLS) Fatal cases of tumour lysis syndrome (TLS) have been reported, some occurring in patients with chronic lymphocytic leukaemia receiving the lowest venetoclax dose used in the dose-titration schedule. For all patients, it is i바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-august-20212021-09-15T10:37:43+01:00Letters and medicine recalls sent to healthcare professionals in August 2021A summary of recent letters, medicine recalls and notifications sent to healthcare professionalstag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-june-20212021-07-07T17:13:08+01:00Letters and medicine recalls sent to healthcare professionals in June 2021 A summary of letters and drug alerts recently sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/erythromycin-caution-required-due-to-cardiac-risks-qt-interval-prolongation-drug-interaction-with-rivaroxaban2020-12-17T17:08:58+00:00Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban Erythromycin has been associated with events secondary to QT interval prolongation such as cardiac arrest and ventricular fibrillation. Erythromycin should not be given to patients with a history of QT interval prolongation바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-november-20202020-12-17T17:08:25+00:00Letters and drug alerts sent to healthcare professionals in November 2020A summary of letters and drug alerts recently sent to healthcare professionals.
tag:www.gov.uk,2005:/drug-safety-update/ferric-carboxymaltose-ferinject-risk-of-symptomatic-hypophosphataemia-leading-to-osteomalacia-and-fractures2020-11-16T16:00:00+00:00Ferric carboxymaltose (Ferinjectâ–¼): risk of symptomatic hypophosphataemia leading to osteomalacia and fracturesMonitor serum phosphate levels in patients treated with multiple high-dose administrations, or those on long-term treatment, and in those with pre-existing risk factors for hypophosphataemia. Re-evaluate ferric carboxymaltos바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-october-20202020-11-16T15:42:11+00:00Letters and drug alerts sent to healthcare professionals in October 2020A summary of letters and drug alerts recently sent to healthcare professionals.
tag:www.gov.uk,2005:/drug-safety-update/warfarin-and-other-anticoagulants-monitoring-of-patients-during-the-covid-19-pandemic2020-10-22T14:15:13+01:00Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemicGuidance has been published on monitoring of patients on warfarin and other anticoagulants during the COVID-19 pandemic.
tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-august-20202020-09-23T14:27:16+01:00Letters and drug alerts sent to healthcare professionals in August 2020A summary of letters and drug alerts recently sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/medical-device-alerts-issued-in-july-20202020-08-26T14:07:07+01:00Medical Device Alerts issued in July 2020A summary of Medical Device Alerts recently issued by the MHRA.tag:www.gov.uk,2005:/drug-safety-update/direct-acting-oral-anticoagulants-doacs-reminder-of-bleeding-risk-including-availability-of-reversal-agents2020-06-29T15:20:07+01:00Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents Remain vigilant for signs and symptoms of bleeding complications during treatment with DOACs (apixaban, dabigatran, edoxaban, rivaroxaban), especially in patients with increased bleeding risks. Specific reversal agents are a바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/immunomodulatory-drugs-and-pregnancy-prevention-temporary-advice-for-management-during-coronavirus-covid-192020-05-21T14:45:46+01:00Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)Guidance has been published about thalidomide, lenalidomide, and pomalidomide and the use of remote consultations and home pregnancy testing for patients taking them during COVID-19.
tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-april-20202020-05-21T14:45:31+01:00Letters and drug alerts sent to healthcare professionals in April 2020A summary of letters and drug alerts recently sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/tofacitinib-xeljanz-new-measures-to-minimise-risk-of-venous-thromboembolism-and-of-serious-and-fatal-infections2020-03-18T14:25:35+00:00Tofacitinib (Xeljanzâ–¼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections Caution should be used in patients with known risk factors for venous thromboembolism in addition to the underlying disease. Patients older than 65 years of age are at an increased risk of serious infections and should be tr바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/baricitinib-olumiant-risk-of-venous-thromboembolism2020-03-18T14:25:18+00:00Baricitinib (Olumiantâ–¼): risk of venous thromboembolism Discontinue baricitinib treatment permanently if clinical features of deep vein thrombosis or pulmonary embolism occur. Prescribers are reminded to use caution if using baricitinib in patients with risk factors for deep vein바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/medical-device-alerts-issued-in-january-20202020-02-12T16:42:52+00:00Medical Device Alerts issued in January 2020Alerts were issued about Convex two-piece skin barriers for use with ostomy bags and HeartStart XL+ defibrillators. A notice was also issued following reports of falsely depressed creatinine results for patients on phenindio바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-december-20192020-01-27T15:33:13+00:00Letters and drug alerts sent to healthcare professionals in December 2019Letters were sent about Insuman insulin products, mecasermin, and valproate medicines. Recalls were issued about ranitidine medicines and Paclitaxel.tag:www.gov.uk,2005:/drug-safety-update/medical-device-alerts-issued-in-december-20192020-01-27T15:32:31+00:00Medical Device Alerts issued in December 2019Alerts were issued about Arrow EZ-IO intraosseous vascular access needle sets, Medicina IV Luer Slip syringes, and Spectra Optia apheresis systems. tag:www.gov.uk,2005:/drug-safety-update/carfilzomib-kyprolis-risk-of-reactivation-of-hepatitis-b-virus2019-11-21T14:57:06+00:00Carfilzomib (Kyprolisâ–¼): risk of reactivation of hepatitis B virusEstablish hepatitis B status before initiating carfilzomib and in patients with unknown hepatitis B virus serology who are already being treated with carfilzomib.
tag:www.gov.uk,2005:/drug-safety-update/nivolumab-opdivo-reports-of-cytomegalovirus-cmv-gastrointestinal-infection-or-reactivation2019-10-18T15:40:33+01:00Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivationPatients on nivolumab who present with diarrhoea or other symptoms of colitis, and those who do not respond to steroid treatment for immune-related colitis, should be investigated to exclude other causes, including infection바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/prescribing-medicines-in-renal-impairment-using-the-appropriate-estimate-of-renal-function-to-avoid-the-risk-of-adverse-drug-reactions2019-10-18T15:40:17+01:00Prescribing medicines in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactionsFor most patients and most medicines, estimated Glomerular Filtration Rate (eGFR) is an appropriate measure of renal function for determining dosage adjustments in renal impairment; however, in some circumstances, the Cockcr바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/daratumumab-darzalex-risk-of-reactivation-of-hepatitis-b-virus2019-08-19T15:48:18+01:00 Daratumumab (Darzalexâ–¼): risk of reactivation of hepatitis B virusEstablish hepatitis B virus status before initiating daratumumab and in patients with unknown hepatitis B virus serology who are already being treated with daratumumab. tag:www.gov.uk,2005:/drug-safety-update/carfilzomib-kyprolis-reminder-of-risk-of-potentially-fatal-cardiac-events2019-08-19T15:47:51+01:00Carfilzomib (Kyprolisâ–¼): reminder of risk of potentially fatal cardiac eventsAnti-cancer therapy with carfilzomib has been associated with cases of cardiac arrest, cardiac failure, and myocardial infarction, including in patients without pre-existing cardiac disorders. Monitor patients for signs and 바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-july-20192019-08-19T15:47:40+01:00Letters and drug alerts sent to healthcare professionals in July 2019Letters were sent about Oncasparâ–¼ (pegaspargase), Ketalar (ketamine) injection, and Elmiron (pentosan polysulfate sodium). A recall was issued for several medicines taken out of the regulated medicines supply chain, includin바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/medical-devices-alerts-issued-in-july-20192019-08-19T15:47:29+01:00 Medical Devices Alerts issued in July 2019Alerts were issued about Telefunken automated external defibrillators and BD Microtainer capillary blood specimen collection tubes. tag:www.gov.uk,2005:/drug-safety-update/rivaroxaban-xarelto-reminder-that-15-mg-and-20-mg-tablets-should-be-taken-with-food2019-07-17T13:36:32+01:00Rivaroxaban (Xareltoâ–¼): reminder that 15 mg and 20 mg tablets should be taken with foodMHRA has received a small number of reports suggesting lack of efficacy (thromboembolic events) in patients taking 15 mg or 20 mg rivaroxaban on an empty stomach; remind patients to take 15 mg or 20 mg rivaroxaban tablets wi바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-june-20192019-07-17T13:34:54+01:00Letters and drug alerts sent to healthcare professionals in June 2019Letters were sent about Myocrisin (sodium aurothiomalate), Cerliponase alfa (Brineuraâ–¼), Darzalexâ–¼(daratumumab), retinoidsâ–¼, and febuxostat (Adenuric). A recall alert was issued for medicines that were taken out of the regul바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/direct-acting-oral-anticoagulants-doacs-increased-risk-of-recurrent-thrombotic-events-in-patients-with-antiphospholipid-syndrome2019-06-19T14:15:12+01:00Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndromeA clinical trial has shown an increased risk of recurrent thrombotic events associated with rivaroxaban compared with warfarin, in patients with antiphospholipid syndrome and a history of thrombosis. Other direct-acting oral바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-may-20192019-06-19T14:12:30+01:00Letters and drug alerts sent to healthcare professionals in May 2019Letters were sent about tofacitinib (Xeljanzâ–¼), Trisenox (arsenic trioxide), lapatinib (Tyverb), direct-acting oral anticoagulants, and Lartruvoâ–¼ (olaratumab). Alerts were issued about Epanutin (phenytoin) oral solution, Mac바카라 사이트¦tag:www.gov.uk,2005:/drug-safety-update/medical-device-alerts-issued-in-may-20192019-06-19T14:12:00+01:00Medical Device Alerts issued in May 2019Alerts were issued about paclitaxel drug coated balloons (DCBs) and implantable drug-eluting stents (DESs) in the treatment of patients with peripheral artery disease, and Aisys and Aisys CS2 anaesthesia devices.
tag:www.gov.uk,2005:/drug-safety-update/tofacitinib-xeljanz-restriction-of-10-mg-twice-daily-dose-in-patients-at-high-risk-of-pulmonary-embolism-while-safety-review-is-ongoing2019-05-17T14:55:22+01:00Tofacitinib (Xeljanzâ–¼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing Following observation in a clinical study of an increased risk of pulmonary embolism and overall mortality with tofacitinib 10 mg twice-daily in rheumatoid arthritis, a safety review has started and new contraindications int바카라 사이트¦